Skip to main content

Table 2 Rates of protection in guinea pigs after challenge with the virulent strain B. melitensis 16 M

From: A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model

Immunization group (prime-boost) Total animals Isolation of B. melitensis in animals, n (%) Value (P)a
( +) controlb (−) controlc
Vector vaccine at dose of 105 EID50 5 2 (40)  > 0.05  > 0.05
Vector vaccine at dose of 106 EID50 5 1 (20)  > 0.05  < 0.05
Vector vaccine at dose of 107 EID50 5 1 (20)  > 0.05  < 0.05
B. melitensis Rev.1 5 1 (20) -  < 0.05
Control (PBS) 5 5 (100)  < 0.05 -
  1. aIn comparison with control untreated PBS or B. melitensis Rev.1 groups
  2. bAnimals immunized with B. melitensis Rev.1 vaccine
  3. cAnimals inoculated with PBS. EID50 50 percent embryo infectious dose
  4. Guinea pigs were immunized twice intranasally 21 days apart with a new vaccine candidate at dose 105 EID50, 106 EID50 and 107 EID50 or a single delivery of the vaccine B. melitensis Rev.1. via s.c. immunization. Animals challenged with virulent strain of B. melitensis 16 M at a dose of 1.3 log10 CFU/animal using subcutaneous route. Statistical analysis was performed using a one-sided Fisher’s exact test. P-value less than 0.05 (< 0.05), P-value higher than 0.05 (> 0.05)